Loading clinical trials...

Utilizing Novel Blood RNA Biomarkers as a Diagnostic Tool in the Identification of Long COVID-19 | Clinical Trials | Clareo Health

RECRUITINGNA

Utilizing Novel Blood RNA Biomarkers as a Diagnostic Tool in the Identification of Long COVID-19

NCT06311435•MaxWell Clinic, PLC

View on ClinicalTrials.gov

Summary

The Primary objective of this study is to determine, using unblinded samples, if it is possible to develop an algorithm for the classification of specific blood RNA from patients with long COVID together and separately from the apparent health normal controls and other medical conditions that share the signs and symptoms of long COVID.

Detailed Description

Participants will be screened and provide two blood samples28 (+/- 2) days apart. Based on the participants survey results they will be placed into one of fourteen groups that reflect the type of Long COVID the patient is experiencing. Samples will be shipped to the sponsor who will develop an AI process to validate the type of Long COVID and assess its severity. The long term goal is to develop a reliable test to identify the presence of Long COVID and its severity.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Mentally capable of understanding and completing informed consent for the study.
•Precipitants with a lab verified diagnosis of SARS-CoV-2 or clinician note/record that an appropriate rapid test for SARS-CoV-2 was positive.
•To qualify for long COVID group participants will need to have new, persistent symptoms related to SARS-CoV-2 infection. iv. No one under the age of 18.

Exclusion Criteria

•Subject is unable to provide informed consent.
•Primary Investigator or Sub-Investigator determines the participant's ongoing medical complaints that began after 1 November 2019 are not related to SARS-COV-2 but another disease process.

Locations (3)

University of Iowa

Iowa City, Iowa, United States

The MaxWell Clinic

Brentwood, Tennessee, United States

The MaxWell Clinic

Brentwood, Tennessee, United States

Key Dates

Start Date

March 15, 2024

Primary Completion Date

March 15, 2026

Completion Date

March 15, 2026

Last Updated

October 18, 2024

Enrollment

224

ESTIMATED participants

Conditions

Long COVID

Interventions

RNA Biomarker Blood Test

DIAGNOSTIC_TEST

Taurine Supplementation in Long COVID

NCT06721949

Long COVID

View study

RECRUITINGPHASE3

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

NCT06631287

Long COVIDSars-CoV-2 Infection+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 18, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Utilizing Novel Blood RNA Biomarkers as a Diagnostic Tool in the Identification of Long COVID-19

Inclusion Criteria

Exclusion Criteria

Taurine Supplementation in Long COVID

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

Presynaptic Imaging in Major Depressive Episodes After COVID-19

Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome

Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome

A Study to Examine Anktiva for the Treatment of COVID-19.